<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The incidence of type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> is increasing worldwide </plain></SENT>
<SENT sid="1" pm="."><plain>The existing therapeutic classes of <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> drugs are not adequately effective in maintaining long-term glycemic control in most patients, even when used in combination </plain></SENT>
<SENT sid="2" pm="."><plain>One emerging novel therapeutic class of <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> drugs is <z:chebi fb="199" ids="26708">sodium</z:chebi> <z:chebi fb="105" ids="17234">glucose</z:chebi> cotransporter 2 (SGLT2) inhibitors </plain></SENT>
<SENT sid="3" pm="."><plain>SGLT2 accounts for 90% of the <z:chebi fb="105" ids="17234">glucose</z:chebi> reabsorption in the kidney </plain></SENT>
<SENT sid="4" pm="."><plain>The SGLT2 inhibitors increase urinary excretion of <z:chebi fb="105" ids="17234">glucose</z:chebi> and lower plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> levels in an insulin-independent manner </plain></SENT>
<SENT sid="5" pm="."><plain>Dapagliflozin, the most prominent molecule in this class, is currently in a phase III clinical trial </plain></SENT>
<SENT sid="6" pm="."><plain>Other members of this class (eg, sergliflozin, remogliflozin) are also in different phases of clinical trials </plain></SENT>
<SENT sid="7" pm="."><plain>This class of novel agents can effectively control blood sugar level without producing <z:mp ids='MP_0005456'>weight gain</z:mp> or <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Results of ongoing phase III clinical trials are crucial to determine whether the risk-benefit ratio will allow approval of this new class of drugs for the management of type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
</text></document>